United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D017277:Drug Approval; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D000077156:Gefitinib; D006801:Humans; D020128:Inhibitory Concentration 50; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008956:Models, Chemical; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib